파비피라비르 (Korean Wikipedia)

Analysis of information sources in references of the Wikipedia article "파비피라비르" in Korean language version.

refsWebsite

Global rank Korean rank

13doi.org

2^nd place

3^rd place

12nih.gov

4^th place

3web.archive.org

1^st place

2reuters.com

49^th place

110^th place

1nhk.or.jp

145^th place

528^th place

1xinhuanet.com

309^th place

632^nd place

1daum.net

832^nd place

7^th place

1elifesciences.org

low place

1mynavi.jp

393^rd place

1,018^th place

1harvard.edu

18^th place

27^th place

1bloomberg.com

99^th place

156^th place

bloomberg.com

Koons C (2014년 8월 7일). “Ebola Drug From Japan May Emerge Among Key Candidates”. Bloomberg.com.

daum.net

news.v.daum.net

강건택 (2020년 4월 1일). “"백악관, 검증안된 일본 약 '아비간' 승인하라고 FDA 압박"”. 연합뉴스. 2020년 4월 1일에 확인함.

doi.org

dx.doi.org

Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD (June 2009). “T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections”. 《Antiviral Research》 82 (3): 95–102. doi:10.1016/j.antiviral.2009.02.198. PMID 19428599.
Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (November 2013). “Favipiravir (T-705), a novel viral RNA polymerase inhibitor”. 《Antiviral Research》 100 (2): 446–54. doi:10.1016/j.antiviral.2013.09.015. PMC 3880838. PMID 24084488.
Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL (April 2014). “Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever”. 《PLOS Neglected Tropical Diseases》 8 (4): e2790. doi:10.1371/journal.pntd.0002790. PMC 3983105. PMID 24722586.
Mumtaz N, van Kampen JJ, Reusken CB, Boucher CA, Koopmans MP (2016). “Zika Virus: Where Is the Treatment?”. 《Current Treatment Options in Infectious Diseases》 8 (3): 208–11. doi:10.1007/s40506-016-0083-7. PMC 4969322. PMID 27547128.
Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A (April 2016). “Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis”. 《The Journal of Infectious Diseases》 213 (8): 1253–61. doi:10.1093/infdis/jiv586. PMC 4799667. PMID 26655300.
Murphy J, Sifri CD, Pruitt R, Hornberger M, Bonds D, Blanton J, Ellison J, Cagnina RE, Enfield KB, Shiferaw M, Gigante C, Condori E, Gruszynski K, Wallace RM (January 2019). “Human Rabies - Virginia, 2017”. 《MMWR. Morbidity and Mortality Weekly Report》 (미국 영어) 67 (5152): 1410–14. doi:10.15585/mmwr.mm675152a2. PMC 6334827. PMID 30605446.
Li G, De Clercq E. Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nature Reviews Drug Discovery 2020 Feb doi:10.1038/d41573-020-00016-0
Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J (2013). “The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase”. 《PLOS One》 8 (7): e68347. Bibcode:2013PLoSO...868347J. doi:10.1371/journal.pone.0068347. PMC 3707847. PMID 23874596.
Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA (April 2013). “T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro”. 《Journal of Virology》 87 (7): 3741–51. doi:10.1128/JVI.02346-12. PMC 3624194. PMID 23325689.
Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen TH, Rodallec A, 외. (March 2018). “Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques”. 《PLOS Medicine》 15 (3): e1002535. doi:10.1371/journal.pmed.1002535. PMC 5870946. PMID 29584730.
Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y (October 2009). “Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells”. 《The Journal of Antimicrobial Chemotherapy》 64 (4): 741–46. doi:10.1093/jac/dkp274. PMC 2740635. PMID 19643775.
Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J (October 2013). “Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)”. 《Molecular Pharmacology》 84 (4): 615–29. doi:10.1124/mol.113.087247. PMID 23907213.
Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, 외. (August 2018). “Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses”. 《Antimicrobial Agents and Chemotherapy》 62 (8): e00766–18. doi:10.1128/AAC.00766-18. PMC 6105843. PMID 29891600.

elifesciences.org

Favipiravir elicits antiviral mutagenesis during virus replication in vivo eLife

harvard.edu

adsabs.harvard.edu

Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J (2013). “The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase”. 《PLOS One》 8 (7): e68347. Bibcode:2013PLoSO...868347J. doi:10.1371/journal.pone.0068347. PMC 3707847. PMID 23874596.

mynavi.jp

news.mynavi.jp

“エボラ出血熱への効果が期待される「アビガン錠」、ノロウイルスにも効果か”. 《マイナビニュース》. 2014년 10월 22일. 2014년 10월 25일에 확인함.

nhk.or.jp

www3.nhk.or.jp

“NHK World News ‘China: Avigan effective in tackling coronavirus’”. 2020년 3월 18일에 원본 문서에서 보존된 문서. 2020년 4월 1일에 확인함.

nih.gov

ncbi.nlm.nih.gov

Furuta Y, Takahashi K, Shiraki K, Sakamoto K, Smee DF, Barnard DL, Gowen BB, Julander JG, Morrey JD (June 2009). “T-705 (favipiravir) and related compounds: Novel broad-spectrum inhibitors of RNA viral infections”. 《Antiviral Research》 82 (3): 95–102. doi:10.1016/j.antiviral.2009.02.198. PMID 19428599.
Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL (November 2013). “Favipiravir (T-705), a novel viral RNA polymerase inhibitor”. 《Antiviral Research》 100 (2): 446–54. doi:10.1016/j.antiviral.2013.09.015. PMC 3880838. PMID 24084488.
Caroline AL, Powell DS, Bethel LM, Oury TD, Reed DS, Hartman AL (April 2014). “Broad spectrum antiviral activity of favipiravir (T-705): protection from highly lethal inhalational Rift Valley Fever”. 《PLOS Neglected Tropical Diseases》 8 (4): e2790. doi:10.1371/journal.pntd.0002790. PMC 3983105. PMID 24722586.
Mumtaz N, van Kampen JJ, Reusken CB, Boucher CA, Koopmans MP (2016). “Zika Virus: Where Is the Treatment?”. 《Current Treatment Options in Infectious Diseases》 8 (3): 208–11. doi:10.1007/s40506-016-0083-7. PMC 4969322. PMID 27547128.
Yamada K, Noguchi K, Komeno T, Furuta Y, Nishizono A (April 2016). “Efficacy of Favipiravir (T-705) in Rabies Postexposure Prophylaxis”. 《The Journal of Infectious Diseases》 213 (8): 1253–61. doi:10.1093/infdis/jiv586. PMC 4799667. PMID 26655300.
Murphy J, Sifri CD, Pruitt R, Hornberger M, Bonds D, Blanton J, Ellison J, Cagnina RE, Enfield KB, Shiferaw M, Gigante C, Condori E, Gruszynski K, Wallace RM (January 2019). “Human Rabies - Virginia, 2017”. 《MMWR. Morbidity and Mortality Weekly Report》 (미국 영어) 67 (5152): 1410–14. doi:10.15585/mmwr.mm675152a2. PMC 6334827. PMID 30605446.
Jin Z, Smith LK, Rajwanshi VK, Kim B, Deval J (2013). “The ambiguous base-pairing and high substrate efficiency of T-705 (Favipiravir) Ribofuranosyl 5'-triphosphate towards influenza A virus polymerase”. 《PLOS One》 8 (7): e68347. Bibcode:2013PLoSO...868347J. doi:10.1371/journal.pone.0068347. PMC 3707847. PMID 23874596.
Baranovich T, Wong SS, Armstrong J, Marjuki H, Webby RJ, Webster RG, Govorkova EA (April 2013). “T-705 (favipiravir) induces lethal mutagenesis in influenza A H1N1 viruses in vitro”. 《Journal of Virology》 87 (7): 3741–51. doi:10.1128/JVI.02346-12. PMC 3624194. PMID 23325689.
Guedj J, Piorkowski G, Jacquot F, Madelain V, Nguyen TH, Rodallec A, 외. (March 2018). “Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques”. 《PLOS Medicine》 15 (3): e1002535. doi:10.1371/journal.pmed.1002535. PMC 5870946. PMID 29584730.
Smee DF, Hurst BL, Egawa H, Takahashi K, Kadota T, Furuta Y (October 2009). “Intracellular metabolism of favipiravir (T-705) in uninfected and influenza A (H5N1) virus-infected cells”. 《The Journal of Antimicrobial Chemotherapy》 64 (4): 741–46. doi:10.1093/jac/dkp274. PMC 2740635. PMID 19643775.
Naesens L, Guddat LW, Keough DT, van Kuilenburg AB, Meijer J, Vande Voorde J, Balzarini J (October 2013). “Role of human hypoxanthine guanine phosphoribosyltransferase in activation of the antiviral agent T-705 (favipiravir)”. 《Molecular Pharmacology》 84 (4): 615–29. doi:10.1124/mol.113.087247. PMID 23907213.
Yoon JJ, Toots M, Lee S, Lee ME, Ludeke B, Luczo JM, 외. (August 2018). “Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses”. 《Antimicrobial Agents and Chemotherapy》 62 (8): e00766–18. doi:10.1128/AAC.00766-18. PMC 6105843. PMID 29891600.

reuters.com

BRIEF-Corrected-Zhejiang Hisun Pharma gets approval for clinical trial to test flu drug Favipiravir for pneumonia caused by new coronavirus. Reuters Healthcare, February 16, 2020.
“Flu drug aimed at Ebola may also fight norovirus, study finds”. Reuters. 2014년 10월 21일. 2014년 10월 25일에 원본 문서에서 보존된 문서. 2014년 10월 22일에 확인함.

web.archive.org

“NHK World News ‘China: Avigan effective in tackling coronavirus’”. 2020년 3월 18일에 원본 문서에서 보존된 문서. 2020년 4월 1일에 확인함.
“Huaxia. "Favipiravir shows good clinical efficacy in treating COVID-19: official." Xinhuanet.com, 17 March 2020”. 2020년 3월 18일에 원본 문서에서 보존된 문서. 2020년 4월 1일에 확인함.
“Flu drug aimed at Ebola may also fight norovirus, study finds”. Reuters. 2014년 10월 21일. 2014년 10월 25일에 원본 문서에서 보존된 문서. 2014년 10월 22일에 확인함.

xinhuanet.com

“Huaxia. "Favipiravir shows good clinical efficacy in treating COVID-19: official." Xinhuanet.com, 17 March 2020”. 2020년 3월 18일에 원본 문서에서 보존된 문서. 2020년 4월 1일에 확인함.